IRIS
DALLIO, MARCELLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.291
NA - Nord America 2.224
AS - Asia 1.819
SA - Sud America 284
Continente sconosciuto - Info sul continente non disponibili 137
AF - Africa 37
OC - Oceania 8
Totale 8.800
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 3.101
US - Stati Uniti d'America 2.135
IT - Italia 631
SG - Singapore 619
CN - Cina 386
IE - Irlanda 244
HK - Hong Kong 235
VN - Vietnam 233
BR - Brasile 226
KR - Corea 99
DE - Germania 86
JP - Giappone 75
GB - Regno Unito 69
IN - India 66
CA - Canada 40
FR - Francia 35
BD - Bangladesh 28
NL - Olanda 25
AR - Argentina 24
MX - Messico 21
AT - Austria 20
FI - Finlandia 19
ID - Indonesia 13
ZA - Sudafrica 13
GR - Grecia 12
EC - Ecuador 11
IQ - Iraq 11
PK - Pakistan 10
ES - Italia 9
PL - Polonia 9
AU - Australia 8
EG - Egitto 8
TR - Turchia 8
CO - Colombia 7
UA - Ucraina 7
UZ - Uzbekistan 7
PY - Paraguay 6
SE - Svezia 5
TT - Trinidad e Tobago 5
CZ - Repubblica Ceca 4
DZ - Algeria 4
KZ - Kazakistan 4
MY - Malesia 4
PE - Perù 4
BB - Barbados 3
CH - Svizzera 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
HN - Honduras 3
JM - Giamaica 3
KE - Kenya 3
LK - Sri Lanka 3
MA - Marocco 3
MK - Macedonia 3
SC - Seychelles 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
BE - Belgio 2
BS - Bahamas 2
ET - Etiopia 2
IR - Iran 2
KG - Kirghizistan 2
LT - Lituania 2
NP - Nepal 2
PH - Filippine 2
PR - Porto Rico 2
AM - Armenia 1
AO - Angola 1
BO - Bolivia 1
GP - Guadalupe 1
GY - Guiana 1
HU - Ungheria 1
IM - Isola di Man 1
JO - Giordania 1
KW - Kuwait 1
KY - Cayman, isole 1
MO - Macao, regione amministrativa speciale della Cina 1
NI - Nicaragua 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PT - Portogallo 1
RO - Romania 1
SA - Arabia Saudita 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
UY - Uruguay 1
Totale 8.663
Salva come PNG Salva come JPEG
Città #
Moscow 1.138
San Jose 314
Singapore 307
Ashburn 249
Dublin 242
Hong Kong 230
Santa Clara 188
Council Bluffs 163
Naples 139
Chandler 108
Seoul 99
Beijing 93
Ho Chi Minh City 90
Hefei 76
New York 62
Milan 59
Hanoi 56
Dallas 45
Los Angeles 40
Boardman 28
Princeton 28
Bengaluru 27
Rome 27
Roxbury 25
Cambridge 22
Munich 22
Bremen 21
São Paulo 21
The Dalles 18
Da Nang 17
Orem 17
Nuremberg 16
Caserta 15
Amsterdam 13
Aversa 13
North Bergen 13
San Francisco 13
Vienna 13
Chicago 12
Mexico City 12
Paris 12
Atlanta 11
Kochi 11
Montreal 11
Boydton 10
Houston 10
Tokyo 10
Toronto 10
Denver 9
Des Moines 9
Frankfurt am Main 9
Phoenix 9
Salerno 9
Memphis 8
Miano 8
Newark 8
Warsaw 8
Belo Horizonte 7
Biên Hòa 7
Boston 7
Brasília 7
Brooklyn 7
Chennai 7
Falkenstein 7
Haiphong 7
Helsinki 7
Medford 7
Ninh Bình 7
Tashkent 7
Turku 7
Baghdad 6
Bari 6
Casoria 6
Castellammare di Stabia 6
Fondi 6
Manchester 6
Piscataway 6
Sennori 6
Viterbo 6
Florence 5
Guangzhou 5
Hillsboro 5
Lappeenranta 5
Mumbai 5
Quito 5
Shanghai 5
Wilmington 5
Bologna 4
Buffalo 4
Camerino 4
Chengdu 4
Curitiba 4
Dhaka 4
Groningen 4
Hangzhou 4
Hyderabad 4
Hải Dương 4
Johannesburg 4
London 4
Manassas 4
Totale 4.490
Salva come PNG Salva come JPEG
Nome #
Integrating Silybin and Sirtuin Related Pathways in Steatosis-Related Liver Diseases 209
A 60-Year-Old Woman with Primary Biliary Cholangitis and Crohn's Ileitis Following the Suspension of Ursodeoxycholic Acid 192
Adherence and Effects Derived from FODMAP Diet on Irritable Bowel Syndrome: A Real Life Evaluation of a Large Follow-Up Observation 188
May chronic cough in chronic obstructive pulmonary disease be a contraindication of Percutaneous Endoscopic Gastrostomy placement: a case report 172
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 168
Dysgeusia in MASLD-related advanced chronic liver disease (ACLD): a silent driver towards the "Bermuda" triangle of malnutrition-sarcopenia-frailty severely affecting prognosis 165
Alcoholic Consumption of Young Italians During the SARS-CoV-2 Pandemic 162
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 158
The bisphenol a induced oxidative stress in non-alcoholic fatty liver disease male patients: A clinical strategy to antagonize the progression of the disease 157
Non-bismuth and bismuth quadruple therapies based on previous clarithromycin exposure are as effective and safe in an area of high clarithromycin resistance: A real-life study 151
The urotensin-II receptor: A marker for staging and steroid outcome prediction in ulcerative colitis 149
The Melanocortin System in Inflammatory Bowel Diseases: Insights into Its Mechanisms and Therapeutic Potentials 148
Inflammatory Bowel Diseases: The Role of Gut Microbiota 148
FLAME: Training and Validating a Newly Conceived Model Incorporating Alpha-Glutathione-S-Transferase Serum Levels for Predicting Advanced Hepatic Fibrosis and Acute Cardiovascular Events in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 147
Light alcohol drinking and the risk of cancer development: a controversial relationship 147
Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis 146
The Lesson from the First Italian Lockdown: Impacts on Anxiety and Depressive Symptoms and Sleep Quality in Patients with Remission of Inflammatory Bowel Disease 144
Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF) 141
Exploring the Epidemiologic Burden, Pathogenetic Features, and Clinical Outcomes of Primary Liver Cancer in Patients with Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Scoping Review 139
Role of Non-Coding RNAs in Hepatocellular Carcinoma Progression: From Classic to Novel Clinicopathogenetic Implications 138
Urotensin II receptor expression in patients with ulcerative colitis: a pilot study 136
Exploring the Classic and Novel Pathogenetic Insights of Plastic Exposure in the Genesis and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 135
Further decompensation in cirrhosis: Results of a large multicenter cohort study supporting Baveno VII statements 134
Intestinal pseudo-obstruction as systemic lupus erythematosus complication: is it time to reconsider the role of surgery? A case report of a tailored multidisciplinary managed 44-year-old male patient 134
Environmental bisphenol A exposure triggers trained immunity-related pathways in monocytes 133
Systemic Oxidative Balance Reflects the Liver Disease Progression Status for Primary Biliary Cholangitis (Pbc): The Narcissus Fountain 133
Extra-Gastric Manifestations of Helicobacter pylori Infection 132
Development of a risk score to predict portal vein tumor thrombosis in patients with hepatocellular carcinoma 130
Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort 130
PNPLA3, TM6SF2, and MBOAT7 Influence on Nutraceutical Therapy Response for Non-alcoholic Fatty Liver Disease: A Randomized Controlled Trial 130
Risk factors for liver decompensation and hcc in hcv-cirrhotic patients after daas: A multicenter prospective study 128
Nutritional and Psychological Support as a Multidisciplinary Coordinated Approach in the Management of Chronic Liver Disease: A Scoping Review 127
Systemic Oxidative Stress Correlates with Sarcopenia and Pruritus Severity in Primary Biliary Cholangitis (PBC): Two Independent Relationships Simultaneously Impacting the Quality of Life—Is the Low Absorption of Cholestasis-Promoted Vitamin D a Puzzle Piece? 126
Beneficial Effects of Silybin Treatment After Viral Eradication in Patients With HCV-Related Advanced Chronic Liver Disease: A Pilot Study 126
Immunity as cornerstone of non-alcoholic fatty liver disease: The contribution of oxidative stress in the disease progression 125
Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)? 124
Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology 124
Spleen Area Affects the Performance of the Platelet Count–Based Non-invasive Tools in Predicting First Hepatic Decompensation in Metabolic Dysfunction–Associated Steatotic Liver Disease Cirrhosis 123
Critical review on the use and abuse of alcohol. When the dose makes the difference 123
The role of fructose in non-alcoholic steatohepatitis: Old relationship and new insights 123
On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites 122
The analysis of alcohol consumption during the severe acute respiratory syndrome coronavirus 2 Italian lockdown 121
Cirrhosis and frailty assessment in elderly patients: A paradoxical result 117
Nutrigenomics and nutrigenetics in metabolic-(Dysfunction) associated fatty liver disease: Novel insights and future perspectives 115
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 114
The influence of acute lifestyle changes on NAFLD evolution in a multicentre cohort: a matter of body composition 112
Predicting de‐novo portal vein thrombosis after HCV eradication: A long‐term competing risk analysis in the ongoing PITER cohort 111
The Role of Insulin Resistance in Fueling NAFLD Pathogenesis: From Molecular Mechanisms to Clinical Implications 110
From “Traditional” to “Trained” Immunity: Exploring the Novel Frontiers of Immunopathogenesis in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 109
Letter: Different Risk of Acute Variceal Bleeding According to the Liver Disease Aetiology in Decompensated Cirrhosis Patients Receiving Carvedilol‐Based Primary Prophylaxis—May Insulin Resistance Unloose This Gordian Knot? 108
Phase Angle/C-reactive Protein-Index as a Novel Combined Tool for Predicting Liver-Related Hospitalizations in MASLD-Decompensated Cirrhosis 108
The Role of the Gut–Biliary–Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications 108
The role of resveratrol in liver disease: A comprehensive review from in vitro to clinical trials 107
Primary biliary cholangitis, Celiac Disease, and MASLD: the triumvirate of steatosis. How should we manage this triple overlap? 106
Urinary volatile Organic compounds in non-alcoholic fatty liver disease (NAFLD), type two diabetes mellitus (T2DM) and NAFLD-T2DM coexistence 102
Is it time to reconsider the MRP6 role in bile secretion and LPAC genetic signature? 102
Beneficial Effects of Long-Lasting Bicarbonate–Sulfate–Calcium–Magnesium Water Intake on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)-Related Outcomes via Impacting Intestinal Permeability (IP), IP-Related Systemic Inflammation, and Oxidative Stress 101
Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV) 96
The Role of Cytokines in the Pathogenesis and Treatment of Alcoholic Liver Disease 92
The Medical Impact of Hepatitis D Virus Infection in Natives and Immigrants: The Italian Paradigm 92
Managing Ascites and Kidney Dysfunction in Decompensated Advanced Chronic Liver Disease: From “One Size Fits All” to a Multidisciplinary-Tailored Approach 89
Safety of Sofosbuvir-Based Direct-Acting Antivirals for Hepatitis C Virus Infection and Direct Oral Anticoagulant Co-Administration 88
Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis 87
Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women 87
Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease 81
Recovery of Bacteroides thetaiotaomicron ameliorates hepatic steatosis in experimental alcohol-related liver disease 79
Long-term albumin improves the outcomes of patients with decompensated cirrhosis and diabetes mellitus: Post hoc analysis of the ANSWER trial 77
The Personalized Management of Primary Biliary Cholangitis in the Era of Precision Medicine: Current Challenges and Future Perspectives 46
From “MAFLD” to “MASLD”: Was This Revolution Worth It? A Head-to-Head Comparison of MAFLD and MASLD Criteria in Estimating Liver Disease Progression and Cardiovascular Risk in Real Life 45
Human Albumin-enriched Peritoneal Dialysis: A Novel Approach to Manage Refractory Ascites and Kidney Dysfunction in Decompensated Advanced Chronic Liver Disease 36
Correction: Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 33
Contrast-enhanced ultrasound as a problem-solving tool and irreversible electroporation for a perivascular/peribiliary segment IVs colorectal liver metastasis: a case report 28
Synbiotic Supplementation for Chronic Constipation in Patients Under Peritoneal Dialysis: An Italian Multicenter Prospective Study 28
Beyond Insulin Resistance: Exploring the Centrality of the Gut–Liver Axis in Mediating Immunometabolic Dysregulation Driving Hepatocellular Carcinoma in MASLD and Diabetes 27
Redefining Liver Transplantation Indications for Hepatic Malignancies in the Era of Precision Transplant Oncology: An Up-to-Date Narrative Review 26
Risk Factors for Inadequate Bowel Preparation Before Colonoscopy in Patients with Ulcerative Colitis in Clinical and Endoscopic Remission: A Multicenter Retrospective Cohort Study 25
Peroxisome Proliferator-Activated Receptor (PPAR) Agonists in Chronic Liver Diseases: Translating Mechanistic Insights into Clinical Practice and Future Perspectives 20
Totale 8.800
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.280
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.280
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022183 0 0 0 22 35 15 7 3 6 11 31 53
2022/2023520 39 13 14 37 84 31 0 26 245 7 10 14
2023/2024382 23 10 12 22 59 62 13 1 21 35 40 84
2024/20251.016 6 17 20 46 155 106 140 100 117 126 96 87
2025/20265.496 223 355 279 212 466 2.902 260 238 180 144 138 99
2026/20271.063 48 187 368 460 0 0 0 0 0 0 0 0
Totale 8.800